(Q36187060)

12 August 2017

1 reference

title

The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. (English)

1 reference

12 August 2017

0 references

6

Graham P Allaway

1 reference

12 August 2017

Susan L Morris-Natschke

4

object named as

Susan L Morris-Natschke

1 reference

12 August 2017

7

Kuo-Hsiung Lee

1 reference

12 August 2017

Donglei Yu

1

1 reference

12 August 2017

Carl T Wild

2

1 reference

12 August 2017

David E Martin

3

1 reference

12 August 2017

Chin-Ho Chen

5

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

6

1 reference

12 August 2017

681-693

1 reference

Targeting HIV: old and new players

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

New antiretroviral agents: looking beyond protease and reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

New targets for inhibitors of HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Current developments in the discovery and design of new drug candidates from plant natural product leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

A new anti-HIV triterpene from Geum japonicum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Immunomodulatory activity of betulinic acid by producing pro-inflammatory cytokines and activation of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Plant-derived terpenoids and analogues as anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Synthesis and anti-HIV activity of 3-alkylamido-3-deoxy-betulinic acid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

The causes and consequences of HIV evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

HIV-1 gag proteins: diverse functions in the virus life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Long-term human hematopoiesis in the SCID-hu mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.681

10.1517/13543784.14.6.681

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference